Inactive Instrument

News Santhera Pharmaceuticals Holding AG Xetra

Equities

S3F

CH0027148649

Summary

Unlock all the news: Be the first to know and act before the market!

Transcript : Santhera Pharmaceuticals Holding AG - Special Call	Jun. 19
Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension	Jun. 18	MT
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting	Jun. 18	AQ
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even	Jun. 18	AQ
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix	Jun. 10	AQ
Santhera Publishes Agenda for its Annual General Meeting	May. 28	AQ
Santhera Publishes Annual Report 2023	May. 28	AQ
Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024	Apr. 25
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	Apr. 25	MT
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	Apr. 25	AQ
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	Apr. 17	MT
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	Mar. 27	MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	Mar. 27	AQ
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	Mar. 27	CI
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	Mar. 14	AQ
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	Feb. 21	CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	Feb. 14	MT
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology	Feb. 14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Santhera Pharmaceuticals Holding AG Xetra

Equities

S3F

CH0027148649

Summary

Filters